Scrutinizing the interactions of Cholinesterase Inhibitors with Amyloid Precursor Protein to Target Alzheimer's Disease

Alzheimer's disease is a fatal brain disorder. It is progressive cognitive disease as it destroys neurons, causing problems with memory, behavior, and finally hampers work. The role of amyloid plaques in the disease is mostly about the β-amyloid protein, which is part of much larger protein called Amyloid precursor protein (APP). Many drug targets have been identified for the disease like APP, tau protein, ubiquitins, all working in different pathways. But the oldest identified cause is APP and is yet under study. Here, we targeted APP with FDA approved cholinesterase inhibitors. Potency levels of these inhibitors were screened against APP and apolipoprotein E which can also be a novel suitable target. It was observed that these inhibitors act approximately the same way on APP. The active distances between these inhibitors and target protein sites were analyzed to screen the firmness of drug binding.